The National Library of Medicine is working on a new interface for PubMed. The new interface will have a more modern look and feel, and will include a variety of new features, such as additional support for mobile devices.
This new interface is currently in beta testing over at PubMed Labs and is publicly available. Users are encouraged to try it and provide their feedback.
Please be aware, since the new interface is still in development, as of now it can’t replace the current PubMed in content and functionality. The National Library of Medicine has announced that not all new/planned features can be found in PubMed Labs yet, but more and more features are being added.
The MSKCC Library is monitoring the progress of these new developments. Once the new PubMed is fully ready for public use, the Library will be offering relevant instruction and assistance.
We hope that the new PubMed will provide an exceptional user experience and support the features users are looking for.
The recent American Association for Cancer Research Annual Meeting placed MSK in the spotlight recently, both for research being performed here and for expert opinions. Here are two such featured items:
- Since 2017, CAR-T therapy has been used as treatment for forms of leukemia and lymphoma. Medical professionals collect and modify a sample of a patient’s immune cells, then return the altered cells to the patient to target and kill cancer cells. MSK’s Prasad Adusumilli and his team developed a CAR-T therapy targeting cancers outside the bloodstream—mesothelioma and lung and breast cancers that spread to the chest wall—and conducted a small phase I clinical trial. The trial found the therapy to be safe and early signs of the immunotherapy’s effectiveness are promising. Read more from the Associated Press, Daily Mail, and The Scientist.
- Two articles quoted MSK’s Monica Morrow’s assessment of a study performed by researchers at Loma Linda University and presented at the meeting. The retrospective study looked at National Cancer Database data from 2010–2012 to determine whether surgery impacted survival for women with HER2+ metastatic breast cancer. It found that women who received surgery were more frequently white, younger, and with private insurance. These socioeconomic factors account at least in part for their improved outcomes after receiving surgery. Dr. Morrow does not believe this study is sufficient to change clinical practice, in large part due to the selection bias in the patient population receiving surgery. She is awaiting results of a randomized trial currently underway.
A selection of cancer research in the news this past week…
- An animal study on breast cancer showed that eating within just an eight-hour window every day could “prevent the development of tumours”. The study’s lead researcher, Dr. Manasi Das, suggested that “this intervention may be effective in breast cancer prevention and therapy”. The study on time restricted eating was formally presented at ENDO 2019 conference (March 23-26, New Orleans).
- Researchers from Tulane University established that circadian disruption caused by exposure to dim light at night may contribute to the metastatic spread of breast cancer to the bone. This animal study was also presented at ENDO 2019 conference.
- Also focused on breast cancer, a trial conducted at Marshall University demonstrated that walnut consumption altered gene expressions related to tumor progression and could “decrease breast cancer growth and survival”. The new study on this ongoing research is in press and is due to be published in Nutrition Research. Note: Primary funding for this study “was from the California Walnut Commission to WEH”.
- Researchers from Mount Sinai Icahn School of Medicine conducted a study that uncovered “how cancer cells with identical genomes can respond differently to the same therapy”. The study published in Nature Communications established the “relationship between mitochondria variability and drug response” which “may lead to more effective targeted cancer treatments”.
- University of Bradford and University of Surrey, UK researchers discovered that prostate cancer cells “spit out” a protein from their nucleus taken up by other cells, including normal cells, which provokes tumor growth. The study was published in Scientific Reports.
- A study conducted by researchers from the UK and Spain determined that a protein produced by melanoma cells triggers reprogramming of healthy immune cells to prevent them from attacking cancer cells and to help them survive instead. The study was published in Cell.